Elevance Health, Inc. (NYSE:ELV – Free Report) – Analysts at Zacks Research lifted their Q2 2027 earnings per share estimates for shares of Elevance Health in a research note issued to investors on Tuesday, November 3rd. Zacks Research analyst Team now anticipates that the company will earn $7.88 per share for the quarter, up from their prior estimate of $7.43. The consensus estimate for Elevance Health’s current full-year earnings is $29.18 per share. Zacks Research also issued estimates for Elevance Health’s Q4 2027 earnings at $4.35 EPS, FY2027 earnings at $29.97 EPS, Q2 2028 earnings at $8.50 EPS and FY2028 earnings at $33.39 EPS.
ELV has been the topic of several other reports. Wall Street Zen downgraded shares of Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Sanford C. Bernstein set a $488.00 price objective on shares of Elevance Health in a report on Thursday, July 16th. Leerink Partners upped their price objective on shares of Elevance Health from $364.00 to $395.00 and gave the company a “market perform” rating in a research note on Friday, July 17th. Cantor Fitzgerald increased their target price on shares of Elevance Health from $400.00 to $450.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Elevance Health in a research report on Thursday, August 13th. Fifteen analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, Elevance Health has an average rating of “Moderate Buy” and an average target price of $456.48.
Read Our Latest Stock Report on ELV
Elevance Health Stock Down 0.1%
Shares of ELV opened at $413.11 on Wednesday. The firm has a market cap of $89.26 billion, a P/E ratio of 17.62, a P/E/G ratio of 1.97 and a beta of 0.63. The stock has a 50 day simple moving average of $411.08 and a two-hundred day simple moving average of $372.73. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.47 and a quick ratio of 1.47. Elevance Health has a 1 year low of $274.84 and a 1 year high of $450.69.
Elevance Health (NYSE:ELV – Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The company reported $6.99 EPS for the quarter, beating the consensus estimate of $4.71 by $2.28. The firm had revenue of $50.44 billion for the quarter, compared to analyst estimates of $49.28 billion. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The company’s revenue was up .7% on a year-over-year basis. During the same period in the prior year, the company earned $6.03 EPS.
Elevance Health Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, December 18th. Stockholders of record on Friday, December 4th will be issued a $1.72 dividend. The ex-dividend date is Friday, December 4th. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. Elevance Health’s dividend payout ratio (DPR) is currently 29.34%.
Insider Activity
In related news, CFO Mark Kaye sold 10,584 shares of Elevance Health stock in a transaction on Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total value of $4,658,335.92. Following the transaction, the chief financial officer directly owned 19,919 shares of the company’s stock, valued at $8,766,949.47. The trade was a 34.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.34% of the company’s stock.
Institutional Investors Weigh In On Elevance Health
Institutional investors have recently added to or reduced their stakes in the company. Meiji Yasuda Asset Management Co Ltd. purchased a new position in Elevance Health during the second quarter valued at $2,086,000. Stoneridge Investment Partners LLC bought a new stake in Elevance Health during the second quarter valued at about $970,000. State Street Corp increased its position in Elevance Health by 1.3% in the second quarter. State Street Corp now owns 10,426,610 shares of the company’s stock worth $4,032,283,000 after buying an additional 137,914 shares in the last quarter. State of Wyoming purchased a new stake in Elevance Health in the second quarter worth about $1,765,000. Finally, Farther Finance Advisors LLC raised its stake in shares of Elevance Health by 27.1% in the third quarter. Farther Finance Advisors LLC now owns 11,826 shares of the company’s stock worth $4,598,000 after buying an additional 2,518 shares during the period. Hedge funds and other institutional investors own 89.24% of the company’s stock.
Elevance Health Company Profile
Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.
Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.
Read More
- Five stocks we like better than Elevance Health
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
